Sumitomo Dainippon Pharma Annual Report 2017
72/102

Millions of yenThousands ofU.S. dollars (Note 1)201620172017See Notes to Consolidated Financial Statements.OPERATING ACTIVITIES:Income before income taxes Adjustments for: Depreciation and amortization Impairment loss Amortization of goodwill Increase (decrease) in liability for retirement benet Provision for other liabilities Interest and dividend income Interest expense Loss (gain) on sales of investment securities Restructuring Loss on discontinuation of R&D programs Changes in assets and liabilities: Decrease (increase) in receivables Decrease (increase) in inventories Increase (decrease) in payables Other — net Subtotal Interest and dividend received Interest paid Payment for restructuring Income taxes paid Net cash provided (used) by operating activities INVESTING ACTIVITIES:Purchases of property, plant and equipment Purchases of intangible assets Proceeds from sales of investment securities Purchases of investment securities Purchase of investments in subsidiaries resulting in change in scope of consolidationNet decrease (increase) in short-term loans receivable Other — net Net cash provided (used) by investing activitiesFINANCING ACTIVITIES:Proceeds from short-term loans payableRepayment of long-term loans Redemption of bondsDividends paid Other — net Net cash provided (used) in nancing activitiesEFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF YEARIncrease (decrease) in cash and cash equivalents resulting from change in the scal period of subsidiariesCASH AND CASH EQUIVALENTS, END OF YEAR (Note 3) ¥ 39,56114,2875535,9801,04518,787(1,657)920(6,107)613—(6,879)(3,026)3,171 (2,417)64,831 1,744 (644) (585)(15,931)49,415(5,383)(4,358)6,383(297)—(2,089)21,63115,8871,080(6,530)(30,000) (7,152)(3)(42,605)(8,224)14,473122,794(1,691)¥ 135,576 ¥ 47,21713,058—5,560(1,664)18,421(1,780)631(5,754)10,8722,006(3,629)(9,266)9,975(8,832)76,815 1,834 (352)(10,849)(45,823)21,625(8,133)(5,327)8,935(357)(84,349)29,855(354)(59,730)39,036(12,000)(10,000)(7,151)(3)9,882(1,749)(29,972)135,576—¥ 105,604$ 421,580116,589—49,643(14,857)164,473(15,893)5,634(51,375)97,07117,911(32,402)(82,732)89,063 (78,857) 685,84816,375 (3,143)(96,866) (409,134)193,080 (72,616) (47,563)79,777 (3,188)(753,116)266,563 (3,160) (533,303)348,536 (107,143)(89,286) (63,848) (27) 88,232(15,616) (267,607)1,210,500—$ 942,893Consolidated Statements of Cash FlowsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016Financial SectionSumitomo Dainippon Pharma Co., Ltd. Annual Report 201771

元のページ  ../index.html#72

このブックを見る